Business
Evolus Raises Full-Year Revenue Guidance on Record Second Quarter 2023 Revenue
Company Increases Full-Year 2023 Net Revenue Guidance to $185 to $195 Million Company Achieved Quarterly Net Revenue of $49.3 Million, Growing 33%
About this update from Evolus, Inc. Common Stock
[{"type":"text","content":"\n\nCompany Increases Full-Year 2023 Net Revenue Guidance to $185 to $195 Million\n\n\n\nCompany Achieved Quarterly Net Revenue of $49.3 Million, Growing 33% Year-over-Year and 10 Percentage Points Above the First Quarter’s Growth Rate\n\n\n\nAchieved Record Growth and All-time Highs in New Accounts, and Consumer Loyalty Enrollments and Redemptions\n\n\n\n NEWPORT BEACH, Calif.--(BUSINESS WIRE)--\nEvolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported revenue for the second quarter ended June 30, 2023 and raised its revenue guidance for the full year.\n\n\nNet revenue for the second quarter of 2023 was $49.3 million, a 33% increase over the corresponding quarter in the prior year, representing a new quarterly record. During the quarter, the company also achieved key performance indicator records including an all-time high since the launch year of nearly 800 new customer accounts, the enrollment of 64,000 new patients and the completion of more than 147,000 patient reward redemptions, having surpassed one million redemptions in its Evolus Rewards™ Patient Loyalty Program earlier this year.\n\n\nDavid Moatazedi, Evolus’ President and Chief Executive Officer, said, “Revenue growth this quarter accelerated by 10 percentage points over the first quarter, reflecting accelerated momentum for Jeuveau® and the exceptional execution of our growth strategy by the entire Evolus team. This accelerating growth and our differentiated business model give us the confidence to raise our 2023 revenue guidance from $180 to $190 million to $185 to $195 million. As we announced in May, we are extremely excited to expand our product portfolio to include a line of five different fillers beginning in 2025, clearly leveraging our strong distribution model and loyalty programs, and accelerating our top-line growth to $700 million by 2028.”\n\n\nThe Company will report its full second quarter financial results on Wednesday, August 2, 2023.\n\n\nConference Call Information\n\n\nManagement will host a conference call and live webcast to discuss Evolus’ financial results August 2 at 4:30 p.m. ET. To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect to the live webcast via the link on the Investor Relations page of our...